STOCK TITAN
  1. Home
  2. News
  3. ATXI

Avenue Therapeutics Inc - ATXI STOCK NEWS

Welcome to our dedicated news page for Avenue Therapeutics (Ticker: ATXI), a resource for investors and traders seeking the latest updates and insights on Avenue Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Avenue Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Avenue Therapeutics's position in the market.

News
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
Rhea-AI Summary
Avenue Therapeutics, Inc. announces a virtual KOL event focusing on spinal bulbar muscular atrophy with experts discussing the potential of AJ201 in SBMA. The Phase 1b/2a study results for AJ201 are expected in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
conferences
-
News
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
Rhea-AI Summary
Avenue Therapeutics completes enrollment in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy, with topline data expected in Q2 2024. Positive preclinical data for BAER-101 presented at key medical meetings. Final agreement with FDA on Phase 3 safety study of IV tramadol.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
Rhea-AI Summary
Avenue Therapeutics, Inc. (ATXI) has been granted an extension by the Nasdaq Hearings Panel to evidence compliance with listing criteria, including bid price and stockholders' equity requirements, until May 20, 2024. The company is exploring options to meet these criteria but cannot guarantee compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
News
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
Rhea-AI Summary
Avenue Therapeutics, Inc. announced that BAER-101 fully suppressed seizure activity in SynapCell's GAERS model of absence epilepsy, demonstrating high efficacy in anti-seizure drug development. The preclinical data showed full seizure suppression with a minimal effective dose of 0.3 mg/kg, PO, supporting its advancement to a Phase 2a trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.63%
Tags
conferences clinical trial
-
News
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
Rhea-AI Summary
Avenue Therapeutics, Inc. announces promising preclinical data on BAER-101 for treating absence epilepsy. The data highlights the compound's ability to suppress seizures effectively with minimal side effects, targeting specific GABAA subtypes. BAER-101 shows significant potential as a safe and potent treatment option for epilepsy patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.7%
Tags
clinical trial
-
News
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
Rhea-AI Summary
Avenue Therapeutics, Inc. (Nasdaq: ATXI) announced that CEO, Dr. Alexandra MacLean, will present a corporate update at the Sidoti January Micro-Cap Investor Conference on January 18, 2024. The company will also host virtual one-on-one meetings with investors. A webcast and archived replay will be available on Avenue's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
Rhea-AI Summary
Avenue Therapeutics, Inc. (Nasdaq: ATXI) announced the entry into warrant exercise agreements with existing accredited investors for the immediate exercise of certain outstanding warrants to purchase an aggregate of 16.5 million shares of the Company’s common stock. The gross proceeds to Avenue from the exercise of the warrants are expected to be approximately $5.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-44.44%
Tags
none
-
News
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
Rhea-AI Summary
Avenue Therapeutics, Inc. (Nasdaq: ATXI) has finalized an agreement with the FDA for the Phase 3 safety study protocol of IV tramadol for the treatment of acute post-operative pain. The study aims to address the theoretical risk of opioid-induced respiratory depression and is expected to be completed within 12 months. The company plans to initiate the study soon, potentially leading to FDA approval and improving the current treatment paradigm for U.S. patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
95.43%
Tags
clinical trial
-
News
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Rhea-AI Summary
Avenue Therapeutics, Inc. (Nasdaq: ATXI) has announced that all patients have been enrolled in the Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA), with topline data anticipated in the second quarter of 2024. The 12-week trial enrolled 25 patients, randomly assigned to AJ201 (600 mg/day) or placebo, with the primary endpoint being the assessment of safety and tolerability of AJ201 in subjects with clinically and genetically defined SBMA. Secondary endpoints include various biomarkers addressing proof of target engagement, including changes in mutant androgen receptor protein levels in skeletal muscle and changes in fat and muscle composition as seen on MRI scans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
clinical trial
News
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
Rhea-AI Summary
Avenue Therapeutics, Inc. (Nasdaq: ATXI) announced that Dr. Amy Chappell will present preclinical data for BAER-101 at the AES 2023 Annual Meeting. The data demonstrate the molecule's potential to significantly suppress seizures in a translational animal model of absence epilepsy. BAER-101 selectively targets GABAA α2 and α3 subtypes, potentially improving anticonvulsant and anxiolytic activity while minimizing the risk of tolerance and abuse. The molecule underwent preclinical evaluation in the GAERS model, demonstrating full suppression of seizure activity with a minimal effective dose of 0.3 mg/kg, PO. The safety, tolerability, and efficacy data support BAER-101's continued development in a Phase 2a trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.43%
Tags
conferences
Stock ATXI logo
Avenue Therapeutics Inc

Nasdaq:ATXI

ATXI Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ATXI Stock Data

5.82M
39.44M
10.88%
2.8%
0.64%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About ATXI

avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.